ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

EBAC European Biotech Acquisition Corporation

11.19
0.00 (0.00%)
27 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
European Biotech Acquisition Corporation NASDAQ:EBAC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 11.19 11.00 12.00 0 00:00:00

Initial Statement of Beneficial Ownership (3)

14/05/2021 4:00pm

Edgar (US Regulatory)


FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Fazeli Mohammad Sohail
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/18/2021 

3. Issuer Name and Ticker or Trading Symbol

European Biotech Acquisition Corp. [EBAC]
(Last)        (First)        (Middle)

C/O EUROPEAN BIOTECH ACQUISITION CORP., JOHANNES VERMEERPLEIN 9
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

AMSTERDAM, P7 1071 DV      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:

Remarks:
No securities beneficially owned.
Exhibit List - Exhibit 24.1 - Power of Attorney
No securities are beneficially owned.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Fazeli Mohammad Sohail
C/O EUROPEAN BIOTECH ACQUISITION CORP.
JOHANNES VERMEERPLEIN 9
AMSTERDAM, P7 1071 DV
X



Signatures
/s/ Gisela Wolf as attorney-in-fact for Mohammad Sohail Fazeli5/14/2021
**Signature of Reporting PersonDate

1 Year European Biotech Acquisi... Chart

1 Year European Biotech Acquisi... Chart

1 Month European Biotech Acquisi... Chart

1 Month European Biotech Acquisi... Chart

Your Recent History

Delayed Upgrade Clock